FR2686899B1
(fr)
*
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
CA2693296C
(en)
|
1997-12-08 |
2013-09-10 |
Merck Patent Gmbh |
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
BR9909583A
(pt)
*
|
1998-04-15 |
2002-01-15 |
Lexigen Pharm Corp |
Aumento da resposta imune mediado por uma proteìna de fusão anticorpo-citocina por co-administração com inibidor de angiogênese
|
US7304150B1
(en)
*
|
1998-10-23 |
2007-12-04 |
Amgen Inc. |
Methods and compositions for the prevention and treatment of anemia
|
EP2311895B1
(de)
|
1999-02-01 |
2017-04-12 |
Eidgenössische Technische Hochschule Zürich |
Biomaterialien die durch nukleophile reaktion auf konjugierten ungesättigten gruppen addiert sind
|
US6958212B1
(en)
|
1999-02-01 |
2005-10-25 |
Eidgenossische Technische Hochschule Zurich |
Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
|
US7345019B1
(en)
*
|
1999-04-13 |
2008-03-18 |
The Kenneth S. Warren Institute, Inc. |
Modulation of excitable tissue function by peripherally administered erythropoietin
|
CZ299516B6
(cs)
|
1999-07-02 |
2008-08-20 |
F. Hoffmann-La Roche Ag |
Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
ATE316982T1
(de)
*
|
1999-08-09 |
2006-02-15 |
Lexigen Pharm Corp |
Mehrere zytokin-antikörper komplexen
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
WO2001036489A2
(en)
|
1999-11-12 |
2001-05-25 |
Merck Patent Gmbh |
Erythropoietin forms with improved properties
|
ATE336514T1
(de)
*
|
2000-02-11 |
2006-09-15 |
Merck Patent Gmbh |
Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
|
US6586398B1
(en)
*
|
2000-04-07 |
2003-07-01 |
Amgen, Inc. |
Chemically modified novel erythropoietin stimulating protein compositions and methods
|
EP1278544A4
(de)
*
|
2000-04-12 |
2004-08-18 |
Human Genome Sciences Inc |
Albumin fusionsproteine
|
ES2237574T5
(es)
*
|
2000-05-15 |
2017-08-09 |
F. Hoffmann-La Roche Ag |
Composición farmacéutica líquida que contiene un derivado de eritropoyetina
|
US7291673B2
(en)
|
2000-06-02 |
2007-11-06 |
Eidgenossiche Technische Hochschule Zurich |
Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
|
WO2001092584A1
(en)
*
|
2000-06-02 |
2001-12-06 |
Eidgenossische Technische Hochschule Zurich |
Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
|
EP1294401B1
(de)
*
|
2000-06-29 |
2007-08-01 |
EMD Lexigen Research Center Corp. |
Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
|
JP5170931B2
(ja)
*
|
2000-10-16 |
2013-03-27 |
中外製薬株式会社 |
Peg修飾エリスロポエチン
|
WO2002055185A2
(en)
|
2000-10-19 |
2002-07-18 |
Eidgenoess Tech Hochschule |
Block copolymers for multifunctional self-assembled systems
|
JP3946638B2
(ja)
*
|
2000-12-11 |
2007-07-18 |
シージェイ コーポレーション |
生体内エリスロポエチン活性が増強された融合蛋白質
|
KR101229995B1
(ko)
*
|
2000-12-11 |
2013-02-06 |
씨제이 주식회사 |
생체내 에리스로포이에틴 활성이 증진된 융합단백질
|
DE60144439D1
(de)
*
|
2000-12-20 |
2011-05-26 |
Hoffmann La Roche |
Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
|
AU2002233230B2
(en)
*
|
2000-12-20 |
2007-02-01 |
F. Hoffmann-La Roche Ag |
Erythropoietin conjugates
|
US7767643B2
(en)
|
2000-12-29 |
2010-08-03 |
The Kenneth S. Warren Institute, Inc. |
Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
|
US20030072737A1
(en)
*
|
2000-12-29 |
2003-04-17 |
Michael Brines |
Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
|
EP1234583A1
(de)
|
2001-02-23 |
2002-08-28 |
F. Hoffmann-La Roche Ag |
PEG-Konjugate des HGF-NK4
|
AU2002248571B2
(en)
*
|
2001-03-07 |
2007-01-18 |
Merck Patent Gmbh |
Expression technology for proteins containing a hybrid isotype antibody moiety
|
WO2002079415A2
(en)
*
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
JP4309662B2
(ja)
*
|
2001-05-03 |
2009-08-05 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
腫瘍特異的組換え抗体およびその使用
|
EP1401477A4
(de)
*
|
2001-05-25 |
2005-02-02 |
Human Genome Sciences |
Chemokin-beta-1-fusionsproteine
|
US6930086B2
(en)
*
|
2001-09-25 |
2005-08-16 |
Hoffmann-La Roche Inc. |
Diglycosylated erythropoietin
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US7795210B2
(en)
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
IL161251A0
(en)
*
|
2001-10-10 |
2004-09-27 |
Neose Technologies Inc |
Remodeling and glycoconjugation of peptides
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
KR100467751B1
(ko)
*
|
2001-12-03 |
2005-01-24 |
씨제이 주식회사 |
생체내 에리스로포이에틴 활성이 증진된 융합단백질
|
EP2354791A1
(de)
*
|
2001-12-04 |
2011-08-10 |
Merck Patent GmbH |
Immunocytokine mit modulierter Selektivität
|
KR100480423B1
(ko)
*
|
2001-12-04 |
2005-04-06 |
선바이오(주) |
에리트로포이에틴과 폴리에틸렌글리콜 유도체의 배합체
|
CN100522946C
(zh)
*
|
2001-12-06 |
2009-08-05 |
法布罗根股份有限公司 |
低氧诱导因子(HIF)α的稳定化
|
EP2277910A1
(de)
|
2001-12-21 |
2011-01-26 |
Human Genome Sciences, Inc. |
Albumin Fusionsproteine
|
EP1463752A4
(de)
*
|
2001-12-21 |
2005-07-13 |
Human Genome Sciences Inc |
Albuminfusionsproteine
|
AU2002351746A1
(en)
*
|
2001-12-21 |
2003-07-15 |
Maxygen Aps |
Erythropoietin conjugates
|
US7300915B2
(en)
|
2002-06-05 |
2007-11-27 |
The Regents Of The University Of California |
Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain
|
BR0312841A
(pt)
*
|
2002-07-24 |
2005-12-06 |
Hoffmann La Roche |
Polipeptìdeo t1249 peguilado
|
RU2296769C2
(ru)
*
|
2002-07-24 |
2007-04-10 |
Ф.Хоффманн-Ля Рош Аг |
Пэгилированный полипептид т20
|
PT1539857E
(pt)
*
|
2002-07-24 |
2007-01-31 |
Hoffmann La Roche |
Derivados de aldeído de polietileno glicol
|
US7459435B2
(en)
|
2002-08-29 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
AU2003273297A1
(en)
*
|
2002-09-09 |
2004-03-29 |
Kenneth S. Warren Institute, Inc. |
Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
|
US7459436B2
(en)
|
2002-11-22 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
WO2004055056A1
(en)
*
|
2002-12-17 |
2004-07-01 |
Merck Patent Gmbh |
Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
|
EP1628618A4
(de)
*
|
2002-12-26 |
2009-09-09 |
Mountain View Pharmaceuticals |
Polymerkonjugate aus zytokinen, chemokinen, wachstumsfaktoren, polypeptidhormonen und antagonisten davon mit konservierter rezeptorbindender aktivität
|
RS20050502A
(en)
*
|
2002-12-26 |
2007-08-03 |
Mountain View Pharmaceuticals Inc., |
Polymer conjugates of interferon- beta with enhanced biological potency
|
WO2004061094A1
(en)
*
|
2002-12-30 |
2004-07-22 |
Gryphon Therapeutics, Inc. |
Water-soluble thioester and selenoester compounds and methods for making and using the same
|
WO2004060966A2
(en)
|
2002-12-31 |
2004-07-22 |
Nektar Therapeutics Al, Corporation |
Maleamic acid polymer derivatives and their bioconjugates
|
ES2335005T5
(es)
*
|
2003-03-05 |
2013-04-17 |
Halozyme, Inc. |
Glicoproteína hialuronidasa soluble (shasegp), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden
|
US7871607B2
(en)
*
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
US20060104968A1
(en)
*
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
US20090123367A1
(en)
*
|
2003-03-05 |
2009-05-14 |
Delfmems |
Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
|
US20040180054A1
(en)
*
|
2003-03-13 |
2004-09-16 |
Hanmi Pharm. Co., Ltd. |
Physiologically active polypeptide conjugate having prolonged in vivo half-life
|
US20050176108A1
(en)
*
|
2003-03-13 |
2005-08-11 |
Young-Min Kim |
Physiologically active polypeptide conjugate having prolonged in vivo half-life
|
BRPI0408358A
(pt)
|
2003-03-14 |
2006-03-21 |
Neose Technologies Inc |
polìmeros hidrossolúveis ramificados e seus conjugados
|
US7642340B2
(en)
|
2003-03-31 |
2010-01-05 |
Xencor, Inc. |
PEGylated TNF-α variant proteins
|
AU2004227937B2
(en)
*
|
2003-03-31 |
2007-09-20 |
Xencor, Inc |
Methods for rational pegylation of proteins
|
US7610156B2
(en)
*
|
2003-03-31 |
2009-10-27 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
MXPA05010773A
(es)
|
2003-04-09 |
2005-12-12 |
Neose Technologies Inc |
Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
EP2336162A1
(de)
*
|
2003-05-12 |
2011-06-22 |
Affymax, Inc. |
Neue polyethylenglycol-modifizierte Agoniste von Erythropoietin und deren Verwendungen
|
RS51130B
(sr)
*
|
2003-05-12 |
2010-10-31 |
Affymax Inc. |
Novi peptidi koji se vezuju za eritropoietinski receptor
|
EP1628686A2
(de)
|
2003-05-12 |
2006-03-01 |
Affymax, Inc. |
Abstandsteil für mit poly (ethylenglycol) modifizierten peptide
|
NZ543935A
(en)
*
|
2003-05-12 |
2008-06-30 |
Affymax Inc |
Peptides that bind to the erythropoietin receptor
|
US7074755B2
(en)
*
|
2003-05-17 |
2006-07-11 |
Centocor, Inc. |
Erythropoietin conjugate compounds with extended half-lives
|
EP1641481A4
(de)
*
|
2003-05-30 |
2008-10-15 |
Centocor Inc |
Bildung von neuen erythropoietin-konjugaten unter verwendung von transglutaminase
|
EP1491554A1
(de)
*
|
2003-06-23 |
2004-12-29 |
CONARIS research institute AG |
PEGlierte lösliche gp130-Dimeren geignet als Medikament
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
CN1882355A
(zh)
*
|
2003-09-09 |
2006-12-20 |
沃伦药品公司 |
保持内源性促红细胞生成素组织保护活性的长效促红细胞生成素
|
CA2539440A1
(en)
*
|
2003-09-29 |
2005-04-14 |
Warren Pharmaceuticals, Inc. |
Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
|
CA2542353A1
(en)
|
2003-10-10 |
2005-04-21 |
Xencor, Inc. |
Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
EP1682584B1
(de)
*
|
2003-11-13 |
2013-04-17 |
Hanmi Science Co., Ltd. |
Pharmazeutische zusammensetzung, die eine immunglobulin-fc-region als träger enthält
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
US7842661B2
(en)
|
2003-11-24 |
2010-11-30 |
Novo Nordisk A/S |
Glycopegylated erythropoietin formulations
|
EP1694347B1
(de)
*
|
2003-11-24 |
2013-11-20 |
BioGeneriX AG |
Glycopegyliertes Erythropoetin
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
US7956032B2
(en)
|
2003-12-03 |
2011-06-07 |
Novo Nordisk A/S |
Glycopegylated granulocyte colony stimulating factor
|
WO2005058366A2
(en)
*
|
2003-12-10 |
2005-06-30 |
Nektar Therapeutics Al, Corporation |
Compositions comprising two different populations of polymer-active agent conjugates
|
JP2007514673A
(ja)
|
2003-12-19 |
2007-06-07 |
エフ.ホフマン−ラ ロシュ アーゲー |
慢性炎症性腸疾患の際の鉄分布障害の処置におけるエリスロポエチンの使用
|
DK1699915T3
(da)
|
2003-12-30 |
2010-09-13 |
Augustinus Bader |
Anvendelse af erythropoietin til levervævsregenerering
|
EP1699821B1
(de)
*
|
2003-12-31 |
2012-06-20 |
Merck Patent GmbH |
Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MIT VERBESSERTER PHARMAKOKINETIK
|
CN101072789B
(zh)
|
2004-01-08 |
2013-05-15 |
生物种属学股份公司 |
肽的o-连接的糖基化
|
CN1942589A
(zh)
*
|
2004-02-02 |
2007-04-04 |
Ambrx公司 |
经修饰的人类生长激素多肽与其用途
|
US7588745B2
(en)
*
|
2004-04-13 |
2009-09-15 |
Si Options, Llc |
Silicon-containing products
|
US20080194475A1
(en)
*
|
2004-04-23 |
2008-08-14 |
Andrew Buchanan |
Erythropoietin Protein Variants
|
US20080300173A1
(en)
|
2004-07-13 |
2008-12-04 |
Defrees Shawn |
Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
|
WO2006031811A2
(en)
|
2004-09-10 |
2006-03-23 |
Neose Technologies, Inc. |
Glycopegylated interferon alpha
|
JP5948627B2
(ja)
|
2004-10-29 |
2016-07-20 |
レイショファーム ゲーエムベーハー |
線維芽細胞成長因子(fgf)のリモデリングと糖質ペグ化
|
US7589063B2
(en)
*
|
2004-12-14 |
2009-09-15 |
Aplagen Gmbh |
Molecules which promote hematopoiesis
|
MX2007005640A
(es)
*
|
2004-11-10 |
2007-08-14 |
Aplagen Gmbh |
Moleculas que promueven la hematopoyesis.
|
WO2006062685A2
(en)
*
|
2004-11-11 |
2006-06-15 |
Affymax, Inc. |
Novel peptides that bind to the erythropoietin receptor
|
WO2006060148A2
(en)
*
|
2004-11-11 |
2006-06-08 |
Affymax, Inc. |
Novel peptides that bind to the erythropoietin receptor
|
EP1858543B1
(de)
|
2005-01-10 |
2013-11-27 |
BioGeneriX AG |
Glycopegylierten Granulocyten-Kolonie-stimulierender Faktor
|
EP1848461A2
(de)
|
2005-02-16 |
2007-10-31 |
Nektar Therapeutics Al, Corporation |
Konjugate einer epo-gruppierung und eines polymers
|
EP2386571B1
(de)
*
|
2005-04-08 |
2016-06-01 |
ratiopharm GmbH |
Zusammensetzungen und Verfahren zur Herstellung von Glycosylierungsmutanten eines Proteaseresistenten menschlichen Wachstumshormons
|
US8329652B2
(en)
*
|
2005-05-10 |
2012-12-11 |
Neoloch Aps |
Neuritogenic peptides
|
US9988427B2
(en)
|
2005-05-13 |
2018-06-05 |
Charite Universitaetsmedizen-Berlin |
Erythropoietin variants
|
EP2975135A1
(de)
|
2005-05-25 |
2016-01-20 |
Novo Nordisk A/S |
Glykopegylierter Faktor IX
|
US9505867B2
(en)
|
2005-05-31 |
2016-11-29 |
Ecole Polytechmique Fédérale De Lausanne |
Triblock copolymers for cytoplasmic delivery of gene-based drugs
|
US7550433B2
(en)
|
2005-06-03 |
2009-06-23 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US8324159B2
(en)
*
|
2005-06-03 |
2012-12-04 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US7919461B2
(en)
|
2005-06-03 |
2011-04-05 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
JP2008546732A
(ja)
*
|
2005-06-23 |
2008-12-25 |
アプラゲン ゲーエムベーハー |
多価化合物
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
JP5198747B2
(ja)
*
|
2005-08-31 |
2013-05-15 |
株式会社カネカ |
ネコ由来タンパク質のコード配列を含む外来性遺伝子を含むトランスジェニック鳥類およびその作製法
|
EP2380435B1
(de)
*
|
2005-08-31 |
2016-05-25 |
Kaneka Corporation |
Von Katzen stammendes Erythropoietin und Herstellungsverfahren dafür
|
JP2009514814A
(ja)
*
|
2005-10-21 |
2009-04-09 |
シナジェバ・バイオファーマ・コーポレイション |
グリコール化およびグリコシル化された家禽類由来の治療用たんぱく質
|
US20080171696A1
(en)
*
|
2005-10-21 |
2008-07-17 |
Avigenics, Inc. |
Pharmacodynamically enhanced therapeutic proteins
|
WO2007056191A2
(en)
|
2005-11-03 |
2007-05-18 |
Neose Technologies, Inc. |
Nucleotide sugar purification using membranes
|
US20150038413A1
(en)
|
2006-02-03 |
2015-02-05 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US7553941B2
(en)
|
2006-02-03 |
2009-06-30 |
Modigene Inc |
Long-acting polypeptides and methods of producing same
|
US8048849B2
(en)
|
2006-02-03 |
2011-11-01 |
Modigene, Inc. |
Long-acting polypeptides and methods of producing same
|
US8759292B2
(en)
|
2006-02-03 |
2014-06-24 |
Prolor Biotech, Llc |
Long-acting coagulation factors and methods of producing same
|
US8048848B2
(en)
|
2006-02-03 |
2011-11-01 |
Prolor Biotech Ltd. |
Long-acting interferons and derivatives thereof and methods thereof
|
US9458444B2
(en)
|
2006-02-03 |
2016-10-04 |
Opko Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
US9249407B2
(en)
|
2006-02-03 |
2016-02-02 |
Opko Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
US8450269B2
(en)
|
2006-02-03 |
2013-05-28 |
Prolor Biotech Ltd. |
Long-acting growth hormone and methods of producing same
|
US8304386B2
(en)
*
|
2006-02-03 |
2012-11-06 |
Prolor Biotech, Inc. |
Long-acting growth hormone and methods of producing same
|
US8476234B2
(en)
*
|
2006-02-03 |
2013-07-02 |
Prolor Biotech Inc. |
Long-acting coagulation factors and methods of producing same
|
US8946155B2
(en)
|
2006-02-03 |
2015-02-03 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US20140113860A1
(en)
|
2006-02-03 |
2014-04-24 |
Prolor Biotech Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US10351615B2
(en)
|
2006-02-03 |
2019-07-16 |
Opko Biologics Ltd. |
Methods of treatment with long-acting growth hormone
|
US10221228B2
(en)
|
2006-02-03 |
2019-03-05 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
CN101062407A
(zh)
|
2006-04-29 |
2007-10-31 |
中国科学院上海生命科学研究院 |
促红细胞生成素在预防或治疗视网膜损伤中的用途
|
US9187532B2
(en)
|
2006-07-21 |
2015-11-17 |
Novo Nordisk A/S |
Glycosylation of peptides via O-linked glycosylation sequences
|
CA2659990C
(en)
|
2006-08-04 |
2016-03-22 |
Prolong Pharmaceuticals, Inc. |
Polyethylene glycol erythropoietin conjugates
|
JP2010505874A
(ja)
*
|
2006-10-03 |
2010-02-25 |
ノヴォ ノルディスク アー/エス |
ポリペプチドコンジュゲートの精製方法
|
CN101600448B
(zh)
*
|
2006-10-04 |
2015-11-25 |
诺和诺德公司 |
甘油连接的peg化的糖和糖肽
|
US20080083154A1
(en)
*
|
2006-10-05 |
2008-04-10 |
Timothy M Gregory |
Bait retention fish hook
|
US20080193942A1
(en)
*
|
2006-11-08 |
2008-08-14 |
Don Wojchowski |
System and method for identifying erythropoietin-responsive genes
|
EP2081956B1
(de)
|
2006-11-13 |
2013-03-20 |
Charité - Universitätsmedizin Berlin |
Zellkulturverfahren und behandlungsverfahren mit einer vepo-protein-variante
|
KR20150064246A
(ko)
|
2007-04-03 |
2015-06-10 |
바이오제너릭스 게엠베하 |
글리코페길화 g―csf를 이용하는 치료 방법
|
CA2690611C
(en)
|
2007-06-12 |
2015-12-08 |
Novo Nordisk A/S |
Improved process for the production of nucleotide sugars
|
EP2018835B1
(de)
|
2007-07-09 |
2014-03-05 |
Augustinus Bader |
Wirkstoff abgebendes Pflaster
|
AR067536A1
(es)
|
2007-07-17 |
2009-10-14 |
Hoffmann La Roche |
Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
|
CL2008002053A1
(es)
|
2007-07-17 |
2009-05-22 |
Hoffmann La Roche |
Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
|
CL2008002092A1
(es)
|
2007-07-20 |
2009-05-29 |
Hoffmann La Roche |
Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
|
US8207112B2
(en)
|
2007-08-29 |
2012-06-26 |
Biogenerix Ag |
Liquid formulation of G-CSF conjugate
|
CN101381412B
(zh)
*
|
2007-09-30 |
2012-02-22 |
深圳赛保尔生物药业有限公司 |
聚合物/重组人促红素偶联物
|
CN101455844B
(zh)
*
|
2007-12-10 |
2011-09-14 |
江苏豪森药业股份有限公司 |
聚乙二醇化促红细胞生成素偶联物和其制备方法与用途
|
US20100286067A1
(en)
*
|
2008-01-08 |
2010-11-11 |
Biogenerix Ag |
Glycoconjugation of polypeptides using oligosaccharyltransferases
|
US8101706B2
(en)
|
2008-01-11 |
2012-01-24 |
Serina Therapeutics, Inc. |
Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
|
WO2009089542A2
(en)
|
2008-01-11 |
2009-07-16 |
Serina Therapeutics, Inc. |
Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
|
CN101939443B
(zh)
|
2008-02-08 |
2014-01-29 |
Ambrx公司 |
经修饰瘦素多肽和其用途
|
WO2009108806A1
(en)
|
2008-02-27 |
2009-09-03 |
Novo Nordisk A/S |
Conjugated factor viii molecules
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
CA2721229C
(en)
|
2008-04-14 |
2022-08-23 |
Halozyme, Inc. |
Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
LT3050576T
(lt)
|
2008-04-29 |
2021-07-12 |
Ascendis Pharma Endocrinology Division A/S |
Pegiliuoti rekombinantinio žmogaus augimo hormono junginiai
|
EP2161031A1
(de)
|
2008-09-05 |
2010-03-10 |
SuppreMol GmbH |
Fc-gamma-Rezeptor zur Behandlung von B-Zellen-vermittelter multipler Sklerose
|
EP2342223B1
(de)
|
2008-09-26 |
2017-04-26 |
Ambrx, Inc. |
Modifizierte tiererythropoietinpolypeptide und anwendungen davon
|
JP5814793B2
(ja)
|
2008-11-25 |
2015-11-17 |
エコール ポリテクニク フェデラル ド ローザンヌ(エーペーエフエル) |
ブロックコポリマーおよびその使用
|
EA022752B1
(ru)
|
2008-12-09 |
2016-02-29 |
Галозим, Инк. |
Длинные растворимые полипептиды рн20 и их использование
|
GB0922354D0
(en)
|
2009-12-21 |
2010-02-03 |
Polytherics Ltd |
Novel polymer conjugates
|
CA2889453C
(en)
|
2009-03-20 |
2018-11-06 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
US9663778B2
(en)
|
2009-07-09 |
2017-05-30 |
OPKO Biologies Ltd. |
Long-acting coagulation factors and methods of producing same
|
JP5734985B2
(ja)
|
2009-09-17 |
2015-06-17 |
バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare SA |
ヒアルロニダーゼおよび免疫グロブリンの安定な共製剤およびそれらの使用方法
|
WO2012003960A1
(en)
|
2010-07-06 |
2012-01-12 |
Augustinus Bader |
Topical application of erythropoietin for the treatment of eye disorders and injuries
|
DK2595624T3
(en)
|
2010-07-20 |
2018-03-26 |
Halozyme Inc |
Methods of treating or preventing adverse side effects associated with administration of an anti-hyaluronan agent
|
RU2566267C2
(ru)
|
2010-09-14 |
2015-10-20 |
Ф. Хоффманн-Ля Рош Аг |
Способ очистки пегилированного эритропоэтина
|
CA2814780C
(en)
|
2010-09-22 |
2017-05-16 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
CN102453087B
(zh)
*
|
2010-10-22 |
2013-12-25 |
广东赛保尔生物医药技术有限公司 |
一种单取代peg-epo的纯化及制备方法
|
JP2014510045A
(ja)
|
2011-02-08 |
2014-04-24 |
ハロザイム インコーポレイテッド |
ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用
|
US9993529B2
(en)
|
2011-06-17 |
2018-06-12 |
Halozyme, Inc. |
Stable formulations of a hyaluronan-degrading enzyme
|
KR101676543B1
(ko)
|
2011-06-17 |
2016-11-15 |
할로자임, 아이엔씨 |
히알루로난 분해효소를 이용한 연속적인 피하 인슐린 주입 방법
|
WO2013040501A1
(en)
|
2011-09-16 |
2013-03-21 |
Pharmathene, Inc. |
Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
|
EP2771028A2
(de)
|
2011-10-24 |
2014-09-03 |
Halozyme, Inc. |
Begleitendes diagnostikum für anti-hyaluronan-therapie und verwendungsverfahren dafür
|
DK3130347T3
(da)
|
2011-12-30 |
2019-10-14 |
Halozyme Inc |
PH20-polypeptidvarianter, formuleringer og anvendelser deraf
|
AU2013243873B2
(en)
|
2012-04-04 |
2016-08-25 |
Halozyme, Inc. |
Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
|
EP2838552A4
(de)
|
2012-04-19 |
2016-05-18 |
Opko Biolog Ltd |
Langwirkende oxyntomodulinvarianten und verfahren zur herstellung davon
|
WO2014062856A1
(en)
|
2012-10-16 |
2014-04-24 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
WO2014080401A2
(en)
|
2012-11-20 |
2014-05-30 |
Prolor Biotech Inc |
Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
|
EP3524691A1
(de)
|
2012-12-07 |
2019-08-14 |
SuppreMol GmbH |
Schichtung und behandlung von patienten von idiopathischer thrombozytopenischer purpura
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ph20玻尿酸酶變異體及其用途
|
US10711106B2
(en)
|
2013-07-25 |
2020-07-14 |
The University Of Chicago |
High aspect ratio nanofibril materials
|
US20150158926A1
(en)
|
2013-10-21 |
2015-06-11 |
Opko Biologics, Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
HUE043847T2
(hu)
|
2014-08-28 |
2019-09-30 |
Halozyme Inc |
Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
|
DK3207130T3
(da)
|
2014-10-14 |
2019-11-11 |
Halozyme Inc |
Sammensætninger af Adenosin Deaminase-2 (ADA2), varianter deraf og fremgangsmåder til anvendelse af samme
|
EP3220892B1
(de)
|
2014-11-21 |
2021-10-13 |
Ascendis Pharma Endocrinology Division A/S |
Langwirkende wachstumshormondosierformen
|
CN113289009A
(zh)
|
2015-06-19 |
2021-08-24 |
Opko生物科学有限公司 |
长效凝固因子及其产生方法
|
EP3428147A4
(de)
|
2016-03-07 |
2019-08-28 |
Hanmi Pharm. Co., Ltd. |
Polyethylenglykolderivat und verwendung davon
|
CN105820232B
(zh)
*
|
2016-04-08 |
2019-05-17 |
昂德生物药业有限公司 |
单修饰聚乙二醇重组人促红素的制备方法及其制品和应用
|
CN118085104A
(zh)
|
2016-07-11 |
2024-05-28 |
Opko生物科学有限公司 |
长效凝血因子及其制备方法
|
CA3027143A1
(en)
|
2016-07-15 |
2018-01-18 |
F. Hoffmann-La Roche Ag |
Method for purifying pegylated erythropoietin
|
WO2018132768A1
(en)
|
2017-01-13 |
2018-07-19 |
Sanna Pietro P |
Methods and compositions for treating hpa hyperactivity
|
KR102268647B1
(ko)
|
2017-06-12 |
2021-06-23 |
한국코러스 주식회사 |
안정성이 향상된 에리스로포이에틴 조성물 및 이의 제조방법
|
KR102675270B1
(ko)
|
2017-06-22 |
2024-06-17 |
버텍스 파마슈티칼스 인코포레이티드 |
변형된 막 유형 세린 프로테아제 1(mtsp-1) 폴리펩티드 및 사용 방법
|
HRP20220388T1
(hr)
*
|
2017-12-29 |
2022-05-27 |
F. Hoffmann - La Roche Ag |
Postupak za dobivanje pegiliranog proteinskog pripravka
|
WO2019222435A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
AU2019413431A1
(en)
|
2018-12-28 |
2021-07-08 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
CN111375068B
(zh)
*
|
2018-12-29 |
2024-04-16 |
江苏豪森药业集团有限公司 |
聚乙二醇化多肽药物的制备方法
|
JP7411189B2
(ja)
*
|
2019-03-29 |
2024-01-11 |
日油株式会社 |
分岐型分解性ポリエチレングリコール結合体
|
WO2022063082A1
(zh)
*
|
2020-09-22 |
2022-03-31 |
美国杰科实验室有限公司 |
一种糖基化修饰的促红细胞生成素及其应用
|